Abstract
Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.
Original language | English |
---|---|
Journal | Neurological research and practice |
Volume | 3 |
Issue number | 1 |
Pages (from-to) | 34 |
ISSN | 2524-3489 |
DOIs | |
Publication status | Published - 21.06.2021 |